CSL Ltd
ASX:CSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CSL Ltd
ASX:CSL
|
AU |
|
Cingulate Inc
NASDAQ:CING
|
US |
|
B
|
BFF Bank SpA
F:2BF
|
IT |
|
G
|
Global Connections PCL
SET:GC
|
TH |
Intrinsic Value
Is CSL undervalued or overvalued?
See the intrinsic value estimate for CSL Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CSL looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with CSL’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What CSL Does
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business.
- Headquarters
- Australia AU
- Employees
- 32 065
- IPO date
- Jun 8, 1994
CSL has no economic moat
Established rivals can supply competing plasma medicines, while generic alternatives limit protection for parts of CSL’s iron treatment business. CSL’s manufacturing expertise and product approvals create hurdles, but do not by themselves keep capable competitors from pursuing its customers and profits.
Read the full moat analysis
Earnings Waterfall
CSL Ltd
The intrinsic value for CSL Ltd (CSL) under the Base Case is hidden AUD.
Compared with the current market price of 186.475 AUD, the stock appears hidden.